BRCA2 and prostate carcinoma: The aim of this study was to quantify the contribution of the founder mutations prevalent in Portugal (BRCA2 c.156_157insAlu and BRCA1 c.3331_3334del) for cancers associated with HBOC other than the common female breast, ovarian, and prostate cancer, more specifically, the rarer pancreatic, male breast, peritoneal, and fallopian tube cancers.